Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany

Cagol, Luana; Seitel, Teresa; Ehrenberg, Sarah; Frivolt, Klára; Krahl, Andreas; Lainka, Elke; Gerner, Patrick; Lenhartz, Henning; Vermehren, Jan; Radkë, Michaël; Trenkel, Stefan; Mayer, Benjamin; Koletzko, Sibylle; Debatin, Klaus‐Michael; Mertens, Thomas; Posovszky, Carsten

doi:10.1016/j.vaccine.2019.12.024

Cited by 16 publications

(20 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirteen studies were related to immunocompromised populations (Fig. 3 ), including three in PLWH (two included only MSM) [ 29 , 50 , 72 ], seven in patients with autoimmune diseases [ 22 , 31 , 34 , 35 , 51 , 53 , 60 ], two in patients with liver cirrhosis resp. after liver transplantation [ 27 , 52 ] and one among those undergoing alcohol-detoxification therapy [ 77 ].…”

Section: Resultsmentioning

confidence: 99%

“…In other immunosuppressed populations, the complete/not specified VC was between 7.8 and 89.0%, with a VC under 40% in nine of ten studies. The study reporting a VC of 89% was conducted in children and adolescents [ 22 ]. For three of 13 studies relating to immunosuppressed populations, the VC with current protection was reported [ 34 , 35 , 52 ].…”

Section: Resultsmentioning

confidence: 99%

“…Reasons for low coverage in this group, including alarmingly low current protection, remain unclear. The high VC in children and adolescents with inflammatory bowel disease or autoimmune hepatitis might be a result of universal vaccination recommendations, rather than one relating specifically to HBV [ 22 ]. Moreover, in this study, a positive attitude among parents towards vaccination was reported.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis B vaccination coverage in Germany: systematic review

et al. 2021

View full text Add to dashboard Cite

Background Despite being considered as a low prevalence country for hepatitis B (HBV), some populations in Germany are at higher risk of infection. In the context of the World Health Organization’s (WHO) viral hepatitis elimination goals, a valid epidemiological data base is needed to plan and monitor the national response. Prevention strategies include general and targeted HBV vaccination programmes. Objective The aim of this work was to estimate the HBV vaccination coverage (VC) in the general population (GP) and different population groups in Germany from available evidence and to identify current evidence gaps for future research. Methods We conducted a systematic review on HBV VC in the general population and populations at high risk of HBV exposure or severe infection in Germany. We included eligible publications (01/01/2017 to 06/06/2020) from databases Embase, Pubmed and Livivo, from a previous scoping review (including data published 01/01/2005–17/03/2017), from the national surveillance system and screened the reference lists of all publications at full text level. Risk of bias was assessed using the Hoy et al. tool. Results We included 68 publications of 67 studies and assigned them to one or more suitable population groups. Twenty-one studies contained data among children/adolescents and three among adults from the GP (VC 65.8–90.5% and 22.9–52.1%, respectively), one among travelers (VC 89.0%), 13 among immunocompromised populations (VC 7.8–89.0%), 16 among populations with occupational risk and 16 with non-occupational risk of HBV exposure (VC 63.6–96.5% and 4.4–84.5%, respectively). Conclusion Comprehensive evidence at low risk of bias was identified for children/adolescents. However, 25 years after including HBV in the national immunisation schedule, VC in Germany is still below the 95%-goal defined by WHO. For people at occupational risk of HBV exposure, VC was mostly reported to be over the WHO goal of 80%, but quality of evidence was heterogenous and should be improved. For people at non-occupational risk of HBV exposure, evidence was sparse and of low quality. The low VC highlights the need for future research to plan vaccination programmes targeting these populations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B vaccination coverage in Germany: systematic review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Grundsätzlich sollte der Impfstatus aber wegen dieser schwierigen Situation deshalb möglichst vor Therapiebeginn überprüftwerden.NachinternationalenEmpfehlungen sollte der Impfstatus schon bei der Erstuntersuchung von RA-Patienten bewertet und Impfstrategien sollten geplant werden, die dann idealerweise während einer stabilen Erkrankung umgesetzt werden sollten [13][14][15]. Obwohl bekannt ist, dass nach einer Impfung immunpathologische Reaktionen auftreten können, insbesondere bei genetisch anfälligen Wirten, deuten Untersuchungen bei RA-Patienten, die mit bDMARDs (Biologika) oder tsDMARDs (JAK-Inhibitoren) behandelt werden, darauf hin, dass Impfstoffe im Rahmen der Immunsuppression sicherer sein könnten als bisher angenommen [16][17][18][19][20][21][22][23][24].…”

Section: Impfung Mit Lebendimpfstoffenunclassified

Ist komplette Immunität gegen Masern bei Patienten mit rheumatischen Erkrankungen ein realistisches Ziel, und wie ist es möglicherweise zu erreichen?

2020

View full text Add to dashboard Cite

Zusammenfassung In Deutschland kommt es immer wieder zu Masernausbrüchen. Patienten mit chronisch entzündlichen Erkrankungen werden oft immunsuppressiv behandelt. In einer aktuellen Studie zeigte sich, dass etwa 7 % dieser Patienten keinen Schutz gegen Maserninfektion haben. Das ergab sich aus der fehlenden Dokumentation im Impfausweis bzw. dem nicht vorhandenen Nachweis von protektiven Antikörpern. Die Ständige Impfkommission (STIKO) empfiehlt eine erste Impfung gegen Masern als Masern-Mumps-Röteln-Kombinationsimpfung (MMR) bei Kindern im Alter von 11–14 Monaten und eine zweite Impfung im Alter von 14–23 Monaten. Für nach 1970 geborene Erwachsene wird eine Impfung gegen Masern empfohlen, wenn diese noch nicht bzw. nur einmal gegen Masern geimpft wurden oder wenn ihr Impfstatus unklar ist. Im April 2019 hat die STIKO Anwendungshinweise zu den bei Immundefizienz empfohlenen Impfungen veröffentlicht. Seit dem 1. März 2020 besteht in Deutschland zudem eine Masernimpfpflicht.

show abstract

“…Using random samples of individuals aged 18 to 79 years drawn between 2008 and 2011, the nationwide health survey DEGS1 reported an unspeci ed VC of 32.9% (by check of vaccination cards and self-report) versus 22.9% (by serological marker) (2, 41). A study of patients from an emergency room in Berlin performed in 2010/2011 showed an unspeci ed VC of 25.2% (self-reported) (56) and in another study complete VC of patients visiting occupational physicians was 52.1%.Regarding travel-related indication for HBV vaccination, one study was identi ed reporting an unspeci ed VC of 89% in a web-based survey(59).Thirteen studies were related to immunocompromised populations including three in PLWH (two of them only including MSM)(28,49,70), seven in patients with autoimmune diseases(21,30,33,34,50,52,58), two in patients with liver cirrhosis resp. after liver transplantation(26,51) and one in alcohol-dependant people during detoxication therapy(75).…”

mentioning

confidence: 99%

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Steffen

Sperle

Harder

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Despite being considered as a low prevalence country for hepatitis B (HBV), some populations in Germany are at higher risk of infection. In the context of the World Health Organization’s (WHO) viral hepatitis elimination goals a valid epidemiological data base is needed to plan and monitor the national response. Prevention strategies include general and targeted HBV vaccination programmes. Objective: The aim of this work was to estimate the HBV vaccination coverage (VC) in the general population (GP) and different population groups in Germany from available evidence and to identify current evidence gaps for future research.Methods: We conducted a systematic review on HBV VC in the general population and populations at high risk of HBV exposure or severe infection in Germany. We included eligible publications (01/01/2017 to 06/06/2020) from databases Embase, Pubmed and Livivo, from a previous scoping review (including data published 01/01/2005-17/03/2017), from the national surveillance system and screened the reference lists of all publications at full text level. Risk of bias was assessed using the Hoy et al tool. Results: We included 68 publications of 67 studies and assigned them to the respective population groups. Twenty-one studies contained data among children/adolescents and three among adults from the GP (VC 65.8% - 90.5% and 22.9% - 52.1%, respectively), one among travellers to HBV endemic countries (VC 89%), 13 among immunocompromised populations (VC 11.5% - 89%), 16 among populations with occupational risk and 16 with non-occupational risk of HBV exposure (VC 63.6% - 96.5% and 4.4% - 52%, respectively). Conclusion: Comprehensive evidence at low risk of bias was identified for children/adolescents. owever, 25 years after including HBV in the national immunisation schedule, VC in Germany is still below the 95%-goal defined by WHO. For people at occupational risk of HBV exposure, VC was mostly reported to be over the WHO goal of 80%, but quality of evidence was heterogenous and should be improved. For people at non-occupational risk of HBV exposure, evidence was sparse and of low quality. The low VC highlights the need for future research to plan vaccination programmes targeting these populations.

show abstract

Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany

Cited by 16 publications

References 47 publications

Hepatitis B vaccination coverage in Germany: systematic review

Hepatitis B vaccination coverage in Germany: systematic review

Ist komplette Immunität gegen Masern bei Patienten mit rheumatischen Erkrankungen ein realistisches Ziel, und wie ist es möglicherweise zu erreichen?

Hepatitis B Vaccination Coverage in Germany: Systematic Review

Contact Info

Product

Resources

About